Wolverine Asset Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Wolverine Asset Management’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,229	Closed	-$261	–	1935
2023 Q4	$261	Sell	5,229 -60,882	-92%	-$6.9K	﹤0.01%	1688
2023 Q3	$14.5K	Sell	66,111 -18,470	-22%	-$3.38K	﹤0.01%	1412
2023 Q2	$11K	Hold	84,581	–	–	﹤0.01%	1376
2023 Q1	$3.47K	Hold	84,581	–	–	﹤0.01%	1590
2022 Q4	$4.23K	Hold	84,581	–	–	﹤0.01%	1769
2022 Q3	$4K	Hold	84,581	–	–	﹤0.01%	2189
2022 Q2	$7K	Hold	84,581	–	–	﹤0.01%	2074
2022 Q1	$30K	Sell	84,581 -29,786	-26%	-$13.1K	﹤0.01%	1677
2021 Q4	$57K	Buy	+114,367	New	+$64.5K	﹤0.01%	1495

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

EFI

EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return

Wolverine Asset Management's CLDI.WS Position: Q1 2024 in Review

Wolverine Asset Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q1 2024, closing a stake of 5,229 shares — an estimated $261 sold.

Wolverine Asset Management first reported a position in CLDI.WS in Q4 2021 and held it in 9 quarters. The position peaked at $57K in Q4 2021. 16 funds tracked by Wall St. Rank hold CLDI.WS as of Q1 2024.

Wolverine Asset Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q1 2024 after selling out during the quarter.
Wolverine Asset Management sold 5,229 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q1 2024, an estimated $261.
Wolverine Asset Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 9 quarters.
Wolverine Asset Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $57K in Q4 2021.
16 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q1 2024.

Based on Wolverine Asset Management's 13F filing for Q1 2024, filed 13 May 2024.